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INTRODUCTION
Breast cancer is the most frequently diagnosed 
cancer in women with over 1.7 Million new cases and 
more than 500,000 patients succumbing to the disease 
every year. While the primary tumor is often detected and 
removed by surgery, 20–40% of patients suffer from tumor 
relapse due to cancer-cell spreading. These metastases that 
are frequently found in bones, lung, liver and the brain are 
the major cause for cancer-related deaths today [1, 2]. One 
critical event during cancer progression is the acquisition 
of a plastic, mesenchymal and motile phenotype by tumor 
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ABSTRACT
Cancer metastasis is the main reason for poor patient survival. Tumor cells 
delaminate from the primary tumor by induction of epithelial-mesenchymal transition 
(EMT). EMT is mediated by key transcription factors, including ZEB1, activated by 
tumor cell interactions with stromal cells and the extracellular matrix (ECM). ZEB1-
mediated EMT and motility is accompanied by substantial cell reprogramming and 
the acquisition of a stemness phenotype. However, understanding of the underlying 
mechanism is still incomplete. We identified hyaluronic acid (HA), one major ECM 
proteoglycan and enriched in mammary tumors, to support EMT and enhance ZEB1 
expression in cooperation with CD44s. In breast cancer cell lines HA is synthesized 
mainly by HAS2, which was already shown to be implicated in cancer progression. 
ZEB1 and HAS2 expression strongly correlates in various cancer entities and high 
HAS2 levels associate with an early relapse. We identified HAS2, tumor cell-derived HA 
and ZEB1 to form a positive feedback loop as ZEB1, elevated by HA, directly activates 
HAS2 expression. In an in vitro differentiation model HA-conditioned medium of breast 
cancer cells is enhancing osteoclast formation, an indicator of tumor cell-induced 
osteolysis that facilitates formation of bone metastasis. In combination with the 
previously identified ZEB1/ESRP1/CD44s feedback loop, we found a novel autocrine 
mechanism how ZEB1 is accelerating EMT.
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cells originating from epithelial tissue. This allows tumor 
cells to delaminate from the primary tumor, break through 
the basement membrane, invade the surrounding tissues 
and eventually enter the blood stream. Upon transport 
to distant sites they extravasate from blood vessels and 
form micrometastases [3, 4]. This metastatic cascade 
requires the activation of embryonic programs: during 
cell spreading the epithelial-mesenchymal transition 
(EMT) is activated, followed by the induction of the 
reverse process, the mesenchymal-epithelial transition 
(MET), to allow colonization. The resulting metastases 
often resemble the primary tumor in grading and marker 
gene expression [1, 4, 5]. Molecularly, EMT is induced 
by the action of specific transcription factors of the ZEB 
(ZEB1/2), Snail (SNAI1/2) and basic helix loop helix 
families (TWIST1) [6–8]. It was shown that ZEB1 is 
a major driver of EMT, tumorigenesis and metastasis 
formation. It provides stemness properties, resistance to 
chemotherapy and its expression correlates with poor 
prognosis [9–13]. ZEB1 acts mainly as transcriptional 
repressor, regulating genes involved in cell adhesion, 
cell polarity and tight junctions as well as key epithelial 
microRNAs. In particular the miR-200 family that induces 
and stabilizes epithelial differentiation is embedded in a 
double negative regulatory feedback loop with ZEB1 
[12, 14–16]. Moreover, ZEB1 induces epigenetic changes 
and cooperates with the Hippo-transducer YAP1 to also 
act as transcriptional activator of specific target genes 
involved in stemness, invasion and metastasis [9, 17, 18]. 
We recently found that ZEB1 also regulates differential 
splicing of the stem cell marker CD44. By repressing 
ESRP1 epithelial-specific CD44v isoforms are switched 
to the standard isoform CD44s that further enhances ZEB1 
expression to maintain an EMT phenotype even in absence 
of external EMT stimuli [19].
Although these findings in part explain the molecular 
downstream function of ZEB1 within the tumor cell, 
efficient invasion and metastasis require interaction with 
the extracellular matrix (ECM) and the surrounding stroma 
as well. It is well known that tumor cells influence ECM 
composition to facilitate migration and invasion into the 
surrounding tissues [20, 21]. Hylaruronan (hyaluronic acid, 
HA) is one ubiquitously expressed simple proteoglycan 
that is present in the ECM. It is required for proper 
embryogenesis and regeneration, but often becomes 
deregulated in disease [20]. HA forms scaffolds for 
ECM assembly, functions as hydrogel to complex water 
molecules and directly signals to cells by interacting with 
a variety of cell surface receptors, including CD44 [20, 22]. 
HA is synthesized in different chain lengths differing in 
molecular weight and molecular function [23]. It was 
demonstrated that HA molecular weight composition is 
altered during tumorigenesis and that this alteration plays 
a major role in tumor progression [24, 25]. The tumor and 
metastasis promoting function is mediated in part by HA 
binding to and subsequent activation of CD44 [26, 27]. 
Autocrine and paracrine signals instruct tumor and stroma 
cells to deposit HA into the ECM, synthesized by three 
hyaluronic acid synthases (HAS1-3) [28]. HAS2 was 
shown to play a crucial role in the context of tumorigenesis. 
Elevated HAS2 expression was correlated with an EMT 
phenotype in over 70% of metaplastic breast carcinoma [29]. 
Recently, it was shown that excess of HA generated by a 
HAS2 transgene in a mouse model for breast cancer, 
accelerated the development of carcinoma [30].
Here we analyzed whether tumor cell secreted HA 
and HAS2 expression is promoting ZEB1-dependent EMT 
and found that HA in combination with CD44s activates 
ZEB1 expression. ZEB1 promotes additional HA synthesis 
by activation of HAS2, thereby generating an additional 
self-enforcing feedback loop involving HA/CD44s, ZEB1 
and HAS2.
RESULTS
Extracellular hyaluronic acid triggers ZEB1 
expression
EMT and malignancy are ultimately connected 
with ECM reconstruction. Deposition of excess HA 
plays an important pro-invasive and pro-metastatic role 
[31]. We aimed to dissect how increased extracellular HA 
contributes to ZEB1-driven EMT and how its synthesis 
and secretion is regulated during tumor progression.
We made use of the triple-negative breast cancer 
cell line MDA-MB231 and its descendent line MDA-
BoM1833, which has been selected for increased 
capacity to form bone metastasis upon injection of the 
parental cell line in mice [32]. Treatment of these two 
mesenchymal-like malignant cell lines with HA induced 
an increase in ZEB1 protein levels (Figure 1A). This 24-h 
short term treatment did not result in ZEB1-dependent 
CD44s accumulation yet. In contrast, addition of HA 
to the epithelial and noninvasive cancer cell line MCF7 
and the mammary fibrocystic cell line MCF10A had 
rather opposite effects leading to further reduction of the 
already low levels of ZEB1, likely owing to the fact that 
one important receptor of HA, CD44s, is not expressed in 
MCF7 and MCF10A (Figure 1A) [19]. In line with this, 
overexpression of CD44s and treatment with extracellular 
HA showed a very robust upregulation of ZEB1 in MCF7 
cells (Figure 1B). Hence, HA supports ZEB1-driven EMT 
that is enhanced by CD44s.
HAS2 in breast cancer cell lines is crucial for 
autocrine HA-dependent activation of ZEB1
To further investigate this finding we interfered 
with autocrine HA synthesis by 4-methylumbelliferone 
(4-MU) treatment [33, 34]. MDA-MB231 and MDA-
BoM1833 cells showed increased levels of HA secretion 
in comparison to the epithelial cell lines MCF7 and 
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MCF10A (Figure 1C). Blocking HA synthesis in 
MDA-MB231 and MDA-BoM1833 resulted in robust 
downregulation of ZEB1 that coincided with reduction in 
CD44s and upregulation of E-cadherin (E-cad) on protein 
and mRNA levels, indicating activation of EMT (Figure 
1D and 1E; Supplementary Figure S1A). Interestingly, 
4-MU treatment also induced downregulation of total 
CD44 levels in contrast to a ZEB1 knockdown that 
induced CD44 isoform switching as shown previously 
(Supplementary Figure S1A) [19].
HA is synthesized by three different hyaluronic 
acid synthases (HAS) encoded by HAS1-3, with different 
properties concerning the molecular size and function 
of the generated HA. In tumors HA is synthesized and 
secreted by stromal as well as by cancer cells. As HAS2 
expression and HAS2-generated HA have been shown to 
promote tumorigenesis, we asked whether HAS2 activity 
induces ZEB1 expression in cancer cells. We used siRNA-
mediated gene silencing that resulted in efficient HAS2 
knockdown and reduced the amount of secreted HA to 
50% and 10% in MDA-MB231 and MDA-BoM1833 
cells, respectively (Figure 1F and 1G; Supplementary 
Figure S1B). This resulted in a slight downregulation 
of ZEB1 protein levels only in MDA-BoM1833 cells, 
whereas transcripts were reduced to 50% and 40% in 
MDA-MB231 and MDA-BoM1833 cells, respectively 
(Figure 1F and Supplementary Figure S1B). Similar to 
the treatment with 4-MU, knockdown of HAS2 led to a 
reduction of CD44s-specific transcripts below 60% in both 
cell lines. Interestingly, the effect of HAS2 knockdown 
was not further enhanced by simultaneous depletion of 
all three HAS genes. Synthesis and secretion of HA was 
not blocked more efficiently, confirming that the majority 
of HA is produced by HAS2 whereas HAS1 and HAS3 
play only minor roles in this context (Figure 1G and 
Supplementary Figure S1C). Taken together, these results 
show that secreted HA plays a key role in regulating ZEB1 
in an autocrine manner. Specifically the enzymatic activity 
of HAS2 is producing HA and promotes ZEB1-induction.
HAS2 strongly correlates with ZEB1 expression 
in tumors and poor prognosis
We wanted to understand whether EMT marker 
expression and HAS2 were correlated in cell lines and 
tumor samples. MDA-MB231 and MDA-BoM1833 cells 
with a mesenchymal phenotype showed low expression of 
E-cad, whereas ZEB1 and CD44s were highly expressed 
(Figure 2A and 2B). In line with increased HA secretion, 
HAS2 was detected at substantial levels in these cell lines 
by Western blotting, immunofluorescence labeling and 
qRT-PCR analysis (Figure 2A and 2C, Supplementary 
Figure S2A). In contrast, the epithelial breast cancer 
and fibrotic cell lines MCF7 and MCF10A showed high 
E-cad levels and low levels of ZEB1, CD44s and HAS2, 
reflecting a weak or absent EMT signature (Figure 2A–2C, 
Supplementary Figure S2A). HAS3 expression was 
indifferent in all cell lines and HAS1 transcripts were 
not detectable (Figure 2C, data not shown). In breast 
cancer tissue sections we found robust co-expression of 
ZEB1 and HAS2 in tumor cell areas, whereas tumor cells 
missing ZEB1 were also negative for HAS2 (Figure 2D, 
Supplementary Figure S2B). This was also reflected by 
a correlation analysis of ZEB1 and HAS2 expression in 
microarray data sets of the CCLE (GSE3613332) [35] 
and the ‘NCI60’ (GSE58463) [36] panels (Figure 2E 
and Supplementary Figure S3). Moreover, genome-
wide transcript analysis of tumor samples confirmed a 
close correlation between ZEB1 and HAS2 (but not with 
HAS1 and HAS3) in breast, pancreas and lung cancer 
specimens (Figure 2F) (GSE42568 [37], GSE28735 [38] 
and GSE41271 [39]). Strikingly, high and low HAS2 
expression levels were associated with differences in the 
period to relapse (Figure 2G and Supplementary Figure 
S4). High HAS2 levels alone already showed correlation 
with poor prognosis (Supplementary Figure S4C). 
Moreover, elevated levels of a HAS2, CD44 and ZEB1 
geneset increased the hazard ratio from 2.84 to 11.47 in 
relapse-free and from 3.147 to 22.78 in overall survival 
studies (Figure 2G, Supplementary Figure S4A and S4C). 
Interestingly, the aggressive claudin-low subtype of 
triple-negative breast cancers showed high expression of 
HAS2, CD44 and ZEB1 (Figure 2H and Supplementary 
Figure S4D). HAS1 and HAS3 showed no correlation to 
survival (Supplementary Figure S4B and S4C). These 
results indicate that HAS2, CD44 and ZEB1 expression 
is correlated in cell lines and tumor samples. HAS2 is 
involved in tumor progression and acts in concert with 
ZEB1-driven EMT.
HAS2 is necessary during TGFβ-induced EMT
To gain further insights into the dynamic changes 
of HAS2 and ZEB1 levels during EMT and how they 
control each other’s expression after initiation of EMT, we 
utilized in vitro systems to induce EMT. MCF10A cells are 
fibrocystic mammary epithelial cells without tumorigenic 
potential in vivo, but they can undergo EMT upon 
TGFβ stimulation or by induction of exogenous ZEB1 
expression [19, 40]. Experimental induction of ZEB1 
from a stably transfected doxycycline (Dox)-inducible 
expression construct in MCF10A cells raised the levels 
of HAS2 protein after seven days of Dox treatment, but 
not in empty vector control cells (Figure 3A). Long-term 
TGFβ stimulation of wildtype MCF10A cells for 21 days 
had similar effects. During EMT induction, ZEB1 levels 
were increased, whereas E-cad became downregulated. 
Concomitantly, HAS2 expression and CD44s splicing 
were induced, as evident on protein level (Figure 3B). 
In line with increased HAS2 levels by TGFβ treatment, 
secreted HA was elevated (Figure 3C). We next analyzed 
MCF10A cells in shorter intervals during the 21 days 
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of TGFβ treatment to observe dynamic changes in gene 
expression during EMT by qRT-PCR. In agreement with 
the endpoint analysis and our previous observations, we 
found a gradual increase of CD44s, ZEB1, vimentin and 
a reduction of E-cad transcripts, whereas total CD44 
levels remained constant, presumably due to alterations 
in ESRP1-regulated splicing (Figure 3D) [19, 41]. 
HAS2 showed a similar gradual increase of transcript 
levels over the entire duration of TGFβ treatment and 
the fold-changes between ZEB1 and HAS2 were of the 
same range, suggesting that their expression is linked 
and regulated by a common mechanism (Figure 3D). 
Knockdown of HAS2 in MCF10A cells during the 21 
days of TGFβ treatment resulted in a complete block of 
EMT. ZEB1 levels were not increased, CD44 differential 
splicing was not shifted towards CD44s and E-cad was 
not downregulated. In comparison to untreated cells, 
siRNA mediated HAS2 knockdown inverted the effects of 
TGFβ and even pushed the cells towards a more epithelial 
phenotype with reduction in ZEB1, vimentin and CD44s 
and increased E-cad levels at the end of the treatment 
(Figure 3E). Knockdown of HAS2 during TGFβ treatment 
Figure 1: Hyaluronic acid (HA) is activating ZEB1 and CD44s expression. (A) Western blot of mesenchymal and epithelial 
breast cancer cell lines showing increasing ZEB1 levels upon HA treatment in MDA-MB231 and MDA-BoM1833 whereas well-
differentiated MCF7 and non-tumorigenic MCF10A cells are not affected. (B) ZEB1 protein levels in Western blots are increased upon 
combined CD44s transfection and HA treatment of MCF7 cells. Exogenous CD44s is stabilized and increased by HA treatment. (C) 
Measurement of secreted HA levels in breast cancer cell lines reveal increased levels in cells with a mesenchymal phenotype. (D) Blocking 
of HA production by 4-MU is inducing MET in MDA-MB231 and MDA-BoM1833 cells evident by decreasing ZEB1 and CD44s levels 
and activation of E-cad in Western blot (E) Quantification of secreted HA upon 4-MU treatment. (F) Western blot of MDA-MB231 and 
MDA-BoM1833 cells upon knockdown of HAS2 shows ZEB1 downregulation, verified by quantification as indicated by numbers below 
individual blots. (G) Quantification of secreted HA in MDA-MB231 and MDA-BoM1833 upon HAS2 knockdown reveals that HAS2 is 
the main enzyme for HA synthesis.
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Figure 2: HAS2 correlates with ZEB1 expression and early relapse in breast cancer. (A) Western blot of MDA-MB231, 
MDA-BoM1833, MCF7 and MCF10A cell lines. HAS2, CD44s and ZEB1 are coexpressed in mesenchymal-like cancer cells, whereas 
inversely only E-cad is expressed in the epithelial cell lines. (B, C) mRNA analysis of CD44s, ZEB1 and E-cad (B) and HAS2 and HAS3 
(C) in the four cell lines. (D) Immunohistochemical staining for ZEB1 and HAS2 on paraffin sections of breast cancer specimen. In ZEB1-
positive tumors, areas of tumor cells that express ZEB1 are also positive for HAS2 (Tumor 2, arrows). In tumors without ZEB1 expression, 
tumor cells show absent or weak expression of HAS2 (Tumor 4). ZEB1-positive stroma cells (open arrowheads) are either HAS2 positive 
or negative. Scale bars, 50 µm (left panel), 20 µm (right panel). (E) Correlation analysis of microarray expression data from breast cancer 
cell lines (‘CCLE panel’, GSE36133). ZEB1 correlates with HAS2, but not with HAS1 and HAS3 expression. (F) Correlation analysis of 
microarray expression data from tumor patients. ZEB1 levels are correlated with HAS2 in breast cancer (GSE42568), but also in pancreas 
(GSE28735) and lung cancer specimens (GSE41271). Pearson correlation coefficients r and p-values were computed and are indicated. 
(G) Kaplan-Meier plots of relapse-free (RFS) survival of upper 58%ile and lower 42%ile of combined high and low expression of HAS2, 
CD44 and ZEB1 (left) and of HAS2 and ZEB1 (right), derived from a microarray and follow-up study collection of 337 tumor samples 
(GSE18229). Increased ZEB1/HAS2/CD44 and to lesser extend increased ZEB1/HAS2 levels are correlated with early relapse. Hazard 
ratios (HR) and logrank p-values are given. (H) Heat map of expression of ZEB1, HAS2 and CD44 in patient samples in (G).
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changed also the shape of the cells to a cobblestone-like 
morphology and formation of epithelial clusters, whereas 
siCtrl transfection did not affect formation of a spindle-
shape morphology and single cell spreading (Figure 3F). 
Similar effects were observed upon siZEB1 and siCD44s 
transfections. These results indicate that both ZEB1 and 
HAS2 are essential for TGFβ-induced EMT and their 
expression is co-regulated, presumably interdependent.
Figure 3: HAS2 becomes activated during EMT along with common EMT markers. (A) MCF10A cells stably transfected 
with a tetracycline-responsive construct for inducible ZEB1 expression, treated with 1 µg/ml doxycycline (Dox) for six days. Western 
blot shows induced ZEB1 and upregulation of HAS2 upon Dox treatment. Quantification of blots are given below the individual blots, 
showing a > 10-fold upregulation of ZEB1 in ‘ZEB1’ cells upon Dox treatment as well as a weak Dox-dependent activation of endogenous 
ZEB1 in ‘Ctrl’ cells. (B) EMT induction of wildtype MCF10A cells by TGFβ treatment for 21 days analyzed by Western blot. E-cad 
is downregulated while CD44s and HAS2 are activated. (C) Treatment of MCF10A cells with TGFβ increases secretion of HA. (D) 
Time-course experiment of TGFβ treatment of MCF10A cells shows a gradual increase of HAS2 levels that follow the increase in ZEB1, 
vimentin and CD44s transcripts by qRT-PCR analysis. Simultaneously, E-cad is downregulated and CD44 total levels remain unchanged. 
(E) Knockdown of HAS2 prevents EMT in TGFβ-treated MCF10A cells. qRT-PCR of transcript levels upon 21-days TGFβ treatment and 
simultaneous knockdown of ZEB1, CD44s or HAS2. Similar to siZEB1 and siCD44s transfection, siHAS2 prevents activation of vimentin, 
CD44s and ZEB1 and E-cad is even increased in comparison to siCtrl samples. (F) Phenotypically, cells are prevented from EMT and stay 
clustered in all transfectants, except for siCtrl samples. Scale bar, 200 µm.
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ZEB1 is activating HAS2 expression by binding 
to the HAS2 promoter
ZEB1 regulates various genes, like miR-200 family 
members, ESRP1 and others in feedback loops [12, 14, 19]. 
To assess whether HAS2 expression is also directly 
controlled by ZEB1, we analyzed HAS2 levels upon ZEB1 
knockdown and ZEB1 occupancy at the HAS2 locus. In 
stable shZEB1 knockdown clones of MDA-MB231 cells 
[42] HAS2 expression was decreased > 100-fold, whereas 
that of HAS3 was 5-fold increased. HAS1 was not detected 
in shGFP or shZEB1 knockdown cells (Figure 4A). The 
decrease in HAS2 levels was confirmed by Western 
blotting (Figure 4B). To distinguish between short and 
long-term effects, we transiently knocked down ZEB1 in 
wildtype MDA-MB231 and MDA-BoM1833 cells and 
observed a similar reduction of HAS2, combined with 
E-cad upregulation upon ZEB1 knockdown (Figure 4C). 
Simultaneous to the loss of HAS2, secreted HA was 
reduced upon siZEB1 transfection in MDA-MB231 
and MDA-BoM1833 cells (Figure 4D). Vice versa, 
overexpression of ZEB1 in the epithelial MCF7 breast 
cancer cell line resulted in downregulation of E-cad and 
a slight activation of HAS2 (Figure 4E). To understand 
whether ZEB1 directly binds to the HAS2 promoter, we 
cloned a -2000 to +1 bp fragment of the human HAS2 
locus upstream of a luciferase reporter gene. Knockdown 
of ZEB1 in MDA-MB231 and MDA-BoM1833 cells 
resulted in reduced activity of the HAS2-luciferase 
reporter construct (Figure 4F). A closer inspection of 
the promoter region identified eight E-boxes as putative 
binding sites for ZEB1 in this construct. Five of them 
were located between -2000 and -1000 bp and three were 
identified at positions -329, -522 and -563 bp (Figure 
4G). We generated deletion constructs del1 and del2 
that harbor the three proximal E-boxes and no E-boxes, 
respectively (Figure 4G). In MCF7 cells the full-length 
construct revealed a 3-fold activation upon transient 
ZEB1 overexpression (Figure 4H). This effect was 
reduced if regions harboring five or all eight E-boxes 
were deleted. However, a moderate 2-fold upregulation 
of the luciferase reporter was observed with the del2 
construct that was not completely diminished in the empty 
vector control (Figure 4H). As we have shown previously 
that ZEB1 is interacting with YAP to activate specific 
common target genes [9], HAS2 might be activated by 
a similar E-box independent mechanism. Chromatin 
immunoprecipitation of the endogenous HAS2 locus in 
MDA-MB231 cells identified a substantial enrichment 
of ZEB1 at the promoter region of HAS2 (−465 bp) in 
contrast to a random distal region at -4500 bp (Figure 4I). 
This enrichment was lost in ZEB1 knockdown cells, 
similar to the known ZEB1 target gene EPCAM 
(Figure 4J). However, we could not identify a specific 
YAP binding to the HAS2 locus, as YAP knockdown did 
not result in decreased ZEB1-mediated precipitation of 
the HAS2 promoter (Figure 4J) and anti-YAP ChIP did not 
show enrichment in shCtrl vs. shYAP cells (Figure 4K). 
Interestingly, HAS2 levels were reduced 2-fold upon YAP 
knockdown, although not significantly (Supplementary 
Figure S5). These results indicate that HAS2 expression 
which is the main driver of HA production in the analyzed 
breast cancer cell lines is directly controlled by ZEB1, 
thereby linking initial EMT signals to the secretion of 
excess HA.
Extracellular HA and conditioned medium 
of MDA-MB231 and MDA-BoM1833 cells 
accelerates osteoclast differentiation in a HAS2-
dependent manner
The life-threatening event during tumor progression 
downstream of EMT is the formation of metastases. It was 
previously shown that HAS2 is crucial for creating a pro-
metastastic microenvironment allowing triple-negative 
breast cancer cells to efficiently colonize to the bone [34, 43]. 
This is in part attributed to enhanced osteolysis by increased 
osteoclast differentiation which is stimulated by HAS2 
and HA [44]. We wondered whether the ZEB1-dependent 
induction of HAS2 and thus increased HA secretion 
enhances osteoclasts differentiation in support of formation 
of a pro-metastatic niche. Therefore we used murine 
monocyte-macrophagic Raw264.7 cells, a well-established 
in vitro model of osteoclast differentiation. In presence of 
RANKL Raw264.7 cells start to form osteoclasts within 
one week, identified by tartrate-resistant acid phosphatase 
(TRAP) staining (Figure 5A and 5B). When these cells 
were incubated with HA in addition to RANKL, the 
amount of differentiated osteoclasts was more than doubled 
from 60 to 130 in a 6-well plate, indicating that external 
supply of HA is promoting osteoclast differentiation 
(Figure 5A and 5B). Importantly, when Raw264.7 cells 
were incubated with supernatant of MDA-MB231 or 
MDA-BoM1833 cells in which ZEB1 was knocked down, 
the amount of osteoclasts was significantly reduced to 
10% in comparison to incubation with control supernatant. 
A similar but less pronounced effect was observed when 
CD44s or HAS2 expression was silenced by siRNA 
in MDA-MB231 or MDA-BoM1833 cells (Figure 5C 
and 5D). These results demonstrate that tumor cell derived 
HA promotes osteoclast differentiation and that the effect is 
dependent on HAS2, CD44s and ZEB1 activities.
DISCUSSION
Besides the deregulation of key signaling pathways, 
tumor progression is dependent on the ability of tumor cells 
to recruit and instruct the microenvironment for providing 
pro-tumorigenic cues. These cues are required to promote 
tumor growth, survival, evasion from immune surveillance 
and metastatic spread by EMT induction [21]. The 
interaction with the microenvironment involves remodeling 
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Figure 4: ZEB1 directly regulates HAS2 expression. (A) mRNA analysis of HAS1, HAS2 and HAS3 levels in MDA-MB231 cells 
after stable ZEB1 knockdown shows a specific loss of HAS2 transcripts whereas HAS3 is even upregulated. HAS1 is not detected (n.d.) in 
shGFP and shZEB1 samples. (B) Western blot analysis of a stable knockdown of ZEB1 in MDA-MB231 cells. (C) Western blot of cells with 
a transient knockdown of ZEB1 in MDA-MB231 and MDA-BoM1833 cells. Knockdown of ZEB1 substantially reduces HAS2 expression. 
(D) Transient ZEB1 knockdown reduces levels of secreted HA in MDA-MB231 and MDA-BoM1833 cells. (E) Overexpression of ZEB1 in 
MCF7 cells induces HAS2 upregulation and E-cad reduction observed by Western blot. (F) Luciferase assay in MDA-MB231 and MDA-
BoM1833 cells transiently transfected with a -2000 bp to +1 bp promoter fragment of the human HAS2 locus cloned 5-prime of a luciferase 
reporter gene. Knockdown of ZEB1 reduces the reporter gene activity. (G) Schematic representation of the human HAS2 promoter region 
between -2000 and +1 bp relative to the transcription start site (TSS). Red lines indicate positions of canonical E- and Z-boxes and primer 
locations used for ChIP are indicated by blue arrows. Sequences included in deletion constructs containing three proximal E-boxes (del1) 
and no E-boxes (del2) are indicated by arrows. (H) Transient transfection of MCF7 cells with the full-length HAS2 promoter construct, del1 
or del2 reveal that co-transfected ZEB1 is activating the full-length construct and to lesser extend the two deletion constructs. (I) Chromatin 
immunoprecipitation (ChIP) using anti-ZEB1 and control IgG in MDA-MB231 cells. Enrichment of ZEB1 is seen at the proximal promoter 
(−465), but not at a distal region of the locus (−4500). (J, K) ChIP of the HAS2 promoter in MDA-MB231 shCtrl, shZEB1 and shYAP stable 
knockdown cells with anti-ZEB1 (J) and anti-YAP (K) antibodies, showing that ZEB1-specific DNA precipitation is lost at HAS2 (−465), 
similar to the promoter of the known ZEB1 target gene EPCAM, whereas ZEB1 binding is unaffected by YAP knockdown.
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of the extracellular matrix, including increased deposition 
of different proteoglycans such as hyaluronic acid into the 
extracellular space [20]. We found tumor cell-derived HA 
to promote EMT, presumably by binding to CD44s. While 
excess HA induced ZEB1 expression, blocking HA synthesis 
reduced ZEB1 levels in triple-negative breast cancer cells. 
Expression of ZEB1 and HAS2, the main synthase of HA 
in tumor cells, was strongly correlated in breast cancer cell 
lines and tumor patient samples and high expression levels 
of HAS2 were associated with poor survival. Interestingly, 
ZEB1 was found to bind to the HAS2 promoter and to 
activate its expression. This suggests another level of 
maintaining an EMT state of tumor cells by enforcing the 
autocrine HA production via ZEB1-mediated transcriptional 
activation of HAS2. HA secretion by tumor cells affected 
not only tumor cells but also the pro-metastatic niche. We 
found that conditioned medium from MDA-MB231 and 
even stronger from the selected bone-metastatic subline 
MDA-BoM1833 enhanced the differentiation of monocytes 
to osteoclasts. This is of particular interest for the formation 
of macrometastases as tumor cells have to remodel the 
bone for efficient colonization [45, 46]. Accordingly, tumor 
cells-derived HA likely interferes with bone homeostasis by 
shifting the equilibrium of bone generating osteoblasts and 
osteolytic osteoclasts towards increased osteoclast numbers 
supporting bone destruction. In line with our findings, 
HAS2 was shown to promote tumor growth and metastases 
in bones by stimulating the interaction of breast cancer 
stem-like cells with macrophages and stromal cells [43]. 
Similarly, inactivating CD44 as the main HA receptor 
by shRNA knockdown blocked metastatic spreading of 
MDA-MB231 cells injected into the mammary fat pad of 
immunodeficient mice. The reduction of bone metastases 
correlated with a decrease in the number of osteolytic 
osteoclasts [44].
In the differentiation experiment of Raw264.7 cells 
conditioned medium of MDA-MB231 or MDA-BoM1833 
cells with a ZEB1 knockdown reduced osteoclast 
differentiation more efficiently than knockdown of HAS2 
and CD44. ZEB1 was shown to induce the expression 
of the BMP inhibitors NOG, FOL and CHRDL1, which 
are secreted and known to promote osteolysis [11, 47]. 
Hence, HA and BMP inhibitors cooperate in bone 
remodeling. Accordingly, knockdown of ZEB1 in the in 
vitro differentiation system had a stronger effect, because 
it is blocking HAS2 expression and HA secretion and is 
reducing BMP-inhibitor accumulation in the conditioned 
medium simultaneously. 
HA synthesis by HAS1-3 and its deposition into the 
ECM is increased during EMT and is known to play a 
Figure 5: HA-enriched conditioned medium of MDA-MB231 and MDA-BoM1833 cells induces osteoclast differentiation 
of Raw264.7 cells to osteoclasts. (A, B) Quantification (A) and morphology (B) of tartrate-resistant acid phosphatase stained osteoclasts 
in cultures of Raw264.7 cells under differentiation conditions with RANKL (Ctrl). Differentiation is enhanced 2.5 fold by additional HA 
treatment (HA). (C, D) Conditioned medium of MDA-MB231 (C) and MDA-BoM1833 cells (D) is providing differentiation cues for 
osteoclast formation of Raw264.7 cells. Knockdown of ZEB1, CD44s and HAS2 reduces the capacity of the conditioned medium to induce 
osteoclast differentiation.
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crucial role during tumor progression [20]. Recently, the 
corresponding synthase genes in mice, in particular Has2 
and Has3, were found among the most highly upregulated 
genes during the early phase of TGFβ-induced EMT. 
This was dependent on Smad4 and the tumor suppressive 
function of TGFβ in a mouse model of pancreatic 
cancer [48]. These findings support our idea that HAS2 is 
induced during EMT by ZEB1 and that its production of 
HA is crucial for sustaining EMT signals.
Of note, it was demonstrated that HAS2 supports 
tumorigenesis mainly by its synthase activity of HA [20]. 
However, an HA-independent function of HAS2 
supporting tumor progression was suggested by recent 
findings. Blocking newly synthesized HA or blocking 
HA-CD44 interaction did not efficiently block EMT in 
TGFβ-treated NMuMG, whereas knockdown of Has2 
completely abolished EMT [49]. Whether an intracellular 
HA-synthase-independent function of HAS2 is active in 
our cellular models could not be sufficiently addressed. 
However, we observed strong effects on ZEB1 levels and 
EMT when HA synthesis was blocked by 4-MU. In line 
with this, CD44s seems to be required for the effect of 
HA on ZEB1 expression, but how HA and CD44s then 
mechanistically act on ZEB1 transcription remains elusive. 
Very likely, HA binds to CD44s which then induces 
signaling by the receptor [26].
Although our results and several other studies 
indicate a pro-tumorigenic function of HA, there are also 
conflicting data that support a more anti-tumorigenic 
function. In squamous cell carcinoma decreased HA levels 
were associated with poor survival. Similarly, in cutaneous 
melanoma reduced HA and CD44 levels lead to an early 
tumor relapse and poor survival [50, 51]. These effects 
might be related to different functions of low, medium and 
high molecular weight HA in a context-dependent manner. 
As an example: high molecular weight HA acts mainly 
anti-angiogenic as it inhibits endothelial proliferation and 
migration in vitro [20]. However, in vivo experiments 
showed that it supports angiogenesis presumably by 
interacting with different ECM components like FGFs 
and proteoglycans [52]. This shows that the function of 
HA is very complex. Moreover, the balance between HA 
synthesis and degradation controls the cellular responses. 
It will be interesting to further explore on this equilibrium 
in breast cancer to obtain a comprehensive view on how 
HA triggers EMT, invasion and metastasis.
Recent findings support the notion that ZEB1 
not only acts as a transcriptional repressor to suppress 
epithelial-specific genes like E-cad and members of the 
miR-200 family, but can also activate transcription in 
specific contexts by interacting with different co-factors 
[9, 11]. Interestingly, this function of ZEB1 does not 
necessarily require direct binding of ZEB1 to the DNA. 
The activation of a specific ZEB1/YAP target gene set 
seems to be independent of any canonical ZEB1 DNA-
binding motif, like Z- or E-boxes at the target gene 
promoters [9]. In our analysis, a reduced expression of 
a HAS2 luciferase reporter construct was detected when 
proximal E-box motifs were deleted. However, ZEB1 was 
still able to partially activate the construct in absence of a 
conserved E-box. Although we have not formally proven 
that ZEB1 is not directly interacting with the DNA of 
the HAS2 promoter, a similar mechanism as for common 
ZEB1/YAP target genes may be active to drive HAS2 
expression. It will be interesting to further dissect how 
ZEB1 is activating the promoter and which transcription 
factors are involved.
In summary, our results provide novel insights 
into how ZEB1 utilizes HAS2/HA to enforce its own 
expression and to shape the microenvironment. This 
crosstalk is used as amplifying module to support the 
previously identified ZEB1/ESRP1/CD44s feedback 
loop [19]. Initial external EMT-stimuli activate ZEB1 
expression that simultaneously provides ligand (HA) 
and generation of the corresponding receptor (CD44s) 
to further accelerate EMT. Activation of (1) CD44 
differential splicing by ESRP1-loss and (2) activation 
of HA synthesis by direct regulation of HAS2 help to 
maintain high ZEB1 expression. In conclusion, together 
with our previous findings, the analysis provides insights 
into a complex multi-factorial feedback system controlled 




MDA-MB231, MCF7, MCF10A and monocyte-
macrophagic Raw264.7 cell lines were purchased from 
ATCC and MDA-BoM1833 were kindly provided by Joan 
Massagué (Sloan-Kettering Institute for Cancer Research, 
New York). MDA-MB231 shGFP and shZEB1 stable 
knockdown clones have been described previously [42] 
and MDA-MB231 shCtrl and shYAP knockdown cells 
were generated by lentiviral transduction of pGIPZ 
constructs harboring a non-silencing control (RHS4346) 
and V3LHS-306099, respectively. Non-transduced cells 
were eliminated by puromycin selection (2.5 µg/ml) for 
3 days. Cells were cultured in DMEM/10% FCS or in 
DMEM/F12 (Invitrogen, 10566 and 31331) supplemented 
with 5% horse serum (Life Technologies, 16050122), 
20 ng/ml EGF (R&D Systems, 236EG200), 0.5 µg/ml 
hydrocortisone (Sigma, H0888), 0.1 µg/ml cholera toxin 
(Sigma, C-8052) and 10 µg/ml insulin (Invitrogen, 12585–
014) for MCF10A cells. EMT was induced by treatment 
with 5 ng/ml TGFβ1 (PeproTech, 100-21) for the indicated 
time replacing the medium every other day. Induction of 
ZEB1 expression in MCF10A cells was induced by adding 
1 µg/ml doxycycline (Dox, Sigma, D9891) every other 
day as described previously [19, 53]. Inhibition of HAS1-3 
to block HA synthesis was performed by treatment of cells 
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with indicated concentrations of 4-Methylumbelliferone 
(4-MU, Sigma, M1381) for 72 h. Hyaluronic acid sodium 
salt from Streptococcus equi bacterial glycosaminoglycan 
polysaccharide (HA, Sigma, 53747-1G) or Sodium 
Hyaluronate 5000 (Healon, 10-2000-12) was dissolved in 
H2O and used at a final concentration of 250–400 µg/ml 
in DMEM/10% FCS for 24 h. All cells were kept at 37°C, 
5% CO2 in a humidified incubator.
Western blotting
Cells were rinsed once in PBS and lysed in TLB. 
30 µg of protein was separated by SDS-PAGE (10%) for 
1 h, 150 V and transferred to a nitrocellulose membrane 
by wet blotting in transfer buffer for 2 h, 300 mA at 4°C. 
Membranes were immersed in Antigen pretreatment 
solution (SuperSignal Westernblot Enhancer, Thermo 
Scientific) for 10 min and blocked in 5% skim milk/
TBST) for 30 min at room temperature. Primary antibody 
incubation was carried out in Primary antibody Diluent 
(SuperSignal Westernblot Enhancer, Thermo, 46641) 
over night at 4°C. After washing in TBST, membrane 
was incubated with HRP-conjugated secondary antibody 
in 5% skim milk/TBST for 1 h at RT. Detection was 
carried out using SuperSignal West Femto Maximum 
Sensitivity Substrate (Thermo, 34094) or ECL Prime 
Westenblot Detection Reagent (Amersham, RPN2232) and 
a ChemiDoc imaging system (BioRad). Quantification was 
performed where appropriate using ImageJ and presented 
normalized to β-Actin levels.
Antibodies
The following antibodies and dilutions were used for 
Western blotting: mouse anti-E-cadherin (BD Pharmingen, 
610181; 1:5,000), mouse anti-β-Actin (Sigma, A5441; 
1:5,000), mouse anti-CD44 (R&D Systems, BBA10; 
1:1000), mouse anti-HAS2 (Abcam, H00054845-B01P; 
1:500) and rabbit anti-ZEB1 (Sigma, HPA027524; 
1:5,000), as well as HRP-coupled goat anti-rabbit IgG 
(Dianova, 111-035-003; 1:25,0000) and goat anti-mouse 
IgG (Dianova, 115-035-003; 1:25,000).
Total RNA isolation and quantitative reverse 
transcriptase PCR (qRT-PCR)
Total RNA was isolated using the RNeasy Plus 
Mini Kit (Qiagen, 74136) according to manufacturer’s 
protocol. cDNA was synthesized from 1 µg total RNA 
with the RevertAid First Strand cDNA Synthesis Kit 
(Thermo, K1622), using 0.5 µl oligo (dT) and 0.5 µl 
random hexamer primers. Transcript levels were analyzed 
by qRT-PCR using cDNA amounts corresponding to 
7.5 ng of original total RNA and 300 nM primers (see 
Supplementary Table S1) with the Power SYBR Green 
PCR Master Mix (Applied Biosystems, 4368702) in a 
LightCycler 480 (Roche). Relative expression levels were 
calculated and normalized to those of ACTB applying the 
Pfaffl method.
Indirect immunofluorescence labeling
Cells were plated on cover slips, fixed with 1% 
PFA/PBS, followed by permeabilization step with 0.25% 
Triton X-100/PBS (10 min each). After blocking in 3% 
BSA/PBS for 30 min, antibodies were diluted 1:200 in 
blocking solution and applied for incubation overnight. 
Alexa488 and −594 conjugated antibodies were used in 
same dilutions for 45–60 min. Cover slips were mounted 
with Citifluor/1 µg/ml DAPI and imaged on a Leica 
DM5500 microscope.
Generation of reporter gene constructs and 
luciferase assay
2 kb of the HAS2 promoter region containing 
E-Boxes at −329, −522, −563, −1065, −1397, −1508, 
−1613 and −1743 bp as well as del1 (−702 to +1 bp) and 
del2 (−248 to +1) sequences were amplified by PfuUltra 
HF polymerase (Agilent, 600380-51) with forward1 (5ʹ-
ataatgagctcaacaacaaatgtgtttttct-3ʹ), forward2 (5ʹ-ataatgag
ctcccacggcagaaacctcttta-3ʹ) or forward3 (5ʹ-ataatgagctccg
gcctgtagctcagagaag-3ʹ) and reverse (5ʹ-ataatagatcttccttcc
ccgccgttgttgc-3ʹ) primers and cloned 5ʹ of the luciferase 
gene into pGL4.10 (Promega) by XhoI/XbaI using 
standard molecular cloning techniques. For the luciferase 
reporter assay, cells were seeded in 24-well plates and 
transfected 24 h later with siRNAs (see Supplementary 
Table S2) and with plasmid DNA another 48 h later. The 
second transfection contained 50 ng pRL-TK, 300 ng 
luciferase reporter construct and 150 ng pCIneo-ZEB1 
or pCIneo empty vector control. Cells were harvested 24 
h after plasmid transfection and lysed in 100 µl passive 
lysis buffer for 15 min and measured by using the Dual-
Luciferase® Reporter Assay System (Promega, E1910) 
according to the manufacturer’s instructions. Firefly 
luciferase levels were normalized to Renilla luciferase 
levels and the activity of the −2000 HAS2 promoter 
construct alone was set to one. Experiments were repeated 
three times.
Transfection of plasmid DNA and siRNA
Plasmid DNA transfection was done by using 
the FugeneHD transfection reagent (Promega, E2311) 
according to the manufacturer’s instructions. siRNAs 
were purchased from Ambion and sequences are provided 
in Supplementary Table S2. 0.4 mM of individual 
siRNAs were transfected with Lipofectamine RNAiMax 
(Invitrogen, 13778075) and unless otherwise indicated 




ChIP was performed as previously described 
[11]. 500 µg of chromatin was incubated with 5 μg of 
anti-ZEB1 (Santa Cruz, H102, sc-25388X) and rabbit 
IgG control (Santa Cruz, sc-2345) antibodies at 4°C 
overnight. 25 µl of a 1:1 ratio of protein A/G Dynabeads 
(Invitrogen,10002D, 10004D) were used to precipitate 
antibody-bound chromatin. Upon elution with 0.1 M 
NaHCO3, 1% SDS and decrosslinking with 250 μg/ml 
RNaseA and 500 μg/ml proteinase K at 65°C overnight, 
specific genomic regions were analyzed by qPCR. Primers 
are given in Supplementary Table S3.
Statistical analysis
Statistical analyses were performed using GraphPad 
Prism 6 (GraphPad Software, Inc.). Normalized relative 
expression levels were used to calculate the mean and 
the SEM for n = 3 unless otherwise stated. Statistical 
significance was evaluated by two-tailed Student’s 
t-test and multi-group comparisons by 2-way ANOVA 
and Tukey’s post-hoc test was used when appropriate. 
p-values of statistical significance are given: *p < 0.05; 
**p < 0.01;***p < 0.001; ****p < 0.0001.
Correlation analysis and Kaplan-Meier plot
Expression data for the ‘CCLE panel’ of cancer cell 
lines comprising 36 cancer types from 917 cancer cell 
lines, the ‘NCI60 panel’ and of 275 lung, 104 breast and 45 
pancreatic cancer patients, including follow-up data, were 
downloaded from the NCBI GEO database (GSE5846, 
GSE36133, GSE41271, GSE42568, GSE28735, 
GSE2034, GSE18229) [35–39, 54, 55]. Correlation 
analysis was done using GraphPad Prism. Relapse and 
overall survival was compared between patients with 
high and low HAS2 expression levels with a cut-off at the 
average expression values above the 58th percentile and 
below the 42th percentile. Kaplan-Meier plotting and log-
rank test was used to evaluate the differences in survival 
between defined groups.
Immunohistochemistry
Samples were retrieved from local archives and usage 
was approved by the Ethics Committee of the University 
of Freiburg. Immunohistochemistry was performed as 
described previously [9] using paraffin embedded tissue, 
sectioned to 4 µm, anti-ZEB1 (Sigma, #HPA027524; 
1:800), anti-HAS2 (Abcam, H00054845-B01P; 1:200) 
antibodies and the EnVision-System (DAKO, K4003, 
K4001). Antigen retrieval was carried out on deparaffinized 
and rehydrated sections in 10 mM citrate buffer, pH 6.0 
in a pressure cooker and DAB substrate (Thermo, 002020) 
was used for visualization of antibody binding. Slides 
were counterstained with Mayer’s hematoxylin (Merck, 
1.09249.0500) and mounted with Histokitt (Roth, 6640).
Osteoclast differentiation assay
The secretome of individual cell lines and transfectants 
was analyzed to promote osteoclast differentiation of 
Raw264.7 cells as previously described [11]. In brief, 
supernatant of MDA-MB231 and MDA-BoM1833 
transfected with siRNAs was collected after 24 h. One 
thousand Raw264.7 cells per well were seeded in a 96-well 
plate and incubated with cell supernatants supplemented 
with 5 ng/ml RANKL (PreproTech, 315-11) as indicated 
with or without 250 ng/ml hyaluronic acid. Tartrate-resistant 
acid phosphatase (TRAP) staining was done with the 
leukocyte acid phosphatase kit (Sigma, 387A-1KT) one 
week afterwards to access the number of osteoclasts.
Enzyme-linked immunosorbent assay (ELISA)
The amount of secreted HA was analyzed by 
Quantikine ELISA Hyaluronan KIT (R&D, DHYAL0). 
Cells were serum-starved for 24 h and medium was 
collected and processed according to the manufacturer’s 
instructions.
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